Evidence map›Paper›PMID 40396182›Full record

ArticleSynthetic biology (Oxford, England)2025

Synthetic biology design principles enable efficient bioproduction of Heparosan with low molecular weight and low polydispersion index for the biomedical industry.

Yadira Boada, Marcelo Flores, Martin Stiebritz, Marco Córdova, Francisco Flores, Alejandro Vignoni

Abstract read
In one paragraph

Article in Synthetic biology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yadira BoadaSynthetic Biology and Biosystems Control Lab, Instituto de Automática e Informática Industrial, Universitat Politècnica de València, Camino de Vera s/n, Valencia 46022, Spain.ORCID https://orcid.org/0000-0001-5677-2702
Marcelo FloresSynthetic Biology and Biosystems Control Lab, Instituto de Automática e Informática Industrial, Universitat Politècnica de València, Camino de Vera s/n, Valencia 46022, Spain.ORCID https://orcid.org/0000-0001-6810-9967
Martin StiebritzLehrstuhl für Biotechnik, Department für Biologie, Friederich-Alexander-Universität, MVC, Henkestraße 91, Erlangen 91052, Germany.ORCID https://orcid.org/0000-0001-8024-4352
Marco CórdovaDepartamento de Ciencias de la Vida y de la Agricultura, Universidad de las Fuerzas Armadas ESPE, Av. Gral. Rumiñahui s/n, Sangolquí 171103, Ecuador.
Francisco FloresDepartamento de Ciencias de la Vida y de la Agricultura, Universidad de las Fuerzas Armadas ESPE, Av. Gral. Rumiñahui s/n, Sangolquí 171103, Ecuador.ORCID https://orcid.org/0000-0001-8092-3750
Alejandro VignoniSynthetic Biology and Biosystems Control Lab, Instituto de Automática e Informática Industrial, Universitat Politècnica de València, Camino de Vera s/n, Valencia 46022, Spain.ORCID https://orcid.org/0000-0001-9977-7132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparosan is a natural polymer with unique chemical and biological properties, that holds great promise for biomedical applications. The molecular weight (Mw) and polydispersion index (PDI) are critical factors influencing the performance of heparosan-based materials. Achieving precise control over the synthesis process to consistently produce heparosan with low Mw and low PDI can be challenging, as it requires tight regulation of reaction conditions, enzyme activity, and precursor concentrations. We propose a novel approach utilizing synthetic biology principles to precisely control heparosan biosynthesis in bacteria. Our strategy involves designing a biomolecular controller that can regulate the expression of genes involved in heparosan biosynthesis. This controller is activated by biosensors that detect heparosan precursors, allowing for fine-tuned control of the polymerization process. Through this approach, we foresee the implementation of this synthetic device, demonstrating the potential to produce low Mw and low PDI heparosan in the probiotic

Indexed as

Biomanufacturingheparosanpolydispersion indexsynthetic biology

Identifiers

PMID40396182
PMCPMC12091141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.